Search hospitals > California > Whittier
Innovative Clinical Research Institute
Claim this profileWhittier, California 90603
Global Leader in Non-Small Cell Lung Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Cancer
123 reported clinical trials
9 medical researchers
Summary
Innovative Clinical Research Institute is a medical facility located in Whittier, California. This center is recognized for care of Non-Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Lymphoma, Cancer and other specialties. Innovative Clinical Research Institute is involved with conducting 123 clinical trials across 105 conditions. There are 9 research doctors associated with this hospital, such as Omkar S Marathe, Richy Agajanian, MD, Amitabha Mazumder, and Paul La Porte.Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
Omkar S MaratheThe Oncology Institute of Hope and Innovation3 years of reported clinical research
Studies Colorectal Cancer
Studies Non-Small Cell Lung Cancer
18 reported clinical trials
31 drugs studied
Richy Agajanian, MDInnovative Clinical Research Institute8 years of reported clinical research
Studies Lymphoma
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
20 drugs studied
Amitabha MazumderThe Oncology Institute of Hope and Innovation5 years of reported clinical research
Studies Lymphoma
Studies Multiple Myeloma
9 reported clinical trials
19 drugs studied
Paul La PorteGSK Investigational Site3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Breast Cancer
10 reported clinical trials
18 drugs studied
Clinical Trials running at Innovative Clinical Research Institute
Non-Small Cell Lung Cancer
Lung Cancer
Lymphoma
Breast Cancer
Solid Tumors
Follicular Lymphoma
Tumors
Polycythemia Vera
Primary Myelofibrosis
Myelofibrosis
Inupadenant + Chemotherapy
for Non-Small Cell Lung Cancer
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.
Recruiting2 awards Phase 27 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Recruiting2 awards Phase 38 criteria
HBI-2438
for Cancer with KRAS G12C Mutation
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Recruiting1 award Phase 16 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Innovative Clinical Research Institute?
Innovative Clinical Research Institute is a medical facility located in Whittier, California. This center is recognized for care of Non-Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Lymphoma, Cancer and other specialties. Innovative Clinical Research Institute is involved with conducting 123 clinical trials across 105 conditions. There are 9 research doctors associated with this hospital, such as Omkar S Marathe, Richy Agajanian, MD, Amitabha Mazumder, and Paul La Porte.